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SUMMARY
Between April and July 2011 there was an outbreak of measles virus, genotype D4, in Berlin,
Germany. We identified 73 case-patients from the community and among students of an
anthroposophic school, who participated in a 4-day school trip, as well as their family and
friends. Overall, 27% were aged 520 years, 57% were female and 15% were hospitalized. Of
39 community case-patients, 38% were aged 520 years, 67% were female and 63% required
hospitalization. Unvaccinated students returning from the school trip were excluded from school,
limiting transmission. Within the group of 55 school-trip participants, including 20 measles
case-patients, a measles vaccine effectiveness of 97·1% (95% confidence interval 83·4–100) for two
doses was estimated using exact Poisson regression. Our findings support school exclusions and
the recommendation of one-dose catch-up vaccination for everyone born after 1970 with
incomplete or unknown vaccination status, in addition to the two-dose routine childhood
immunization recommendation.
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INTRODUCTION
Measles has been targeted for elimination in the WHO
European region since 1998 [1, 2]. Initially, progress
towards the target was made. However, in Germany
and several other member states, large measles
outbreaks continued to occur [3] and increased
transmission has been observed in Europe since late
2009 [4–6]. Since 2001, suspected and confirmed
measles cases in Germany must be notified by clin-
icians and laboratories according to the Protection
against Infection Act. Reported national annual inci-
dence rates during 2006–2010 ranged between 0·69
and 2·80/100000 population [7] with substantial over-
all decline since 2003 and interrupted transmission
of indigenous measles virus (MV) variants [8]. Local
and regional outbreaks have occurred sporadically
since 2005 and since 2004 an increasing proportion
of adult cases has been observed [8–10]. The last out-
break in Berlin was reported in 2010 consisting of
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62 reported cases [11]. The annual incidence from
2006 to 2010 in Berlin ranged between 0·23 and
2·66/100000 [7].
In 1970, the former German Democratic Republic
(East Germany) introduced a mandatory one-dose
measles vaccination programme for all children.
Since 1974, The Federal Republic of Germany
(West Germany) recommended one-dose measles
vaccination. In the reunited Germany, two doses of
measles-containing vaccine (MCV) have been recom-
mended since 1991. Since 2001, the recommended
age for vaccination is 11–14 months (first dose) and
15–23 months (second dose) with opportunistic
catch-up until age 18 years [10, 12]. The national vac-
cination coverage assessed for children aged 5–6 years,
using retrospective assessment at school entry, was
96·4% for one dose and 91·5% for two doses of
MCV in 2010 [13]. In order to address the accumu-
lation of adults susceptible to measles, as indicated
by the increased proportion of notified adult measles
cases, the vaccination recommendation was expanded
in 2010 to include one MCV dose for all adults born
after 1970 with unknown vaccination status, no vacci-
nation or only one MCV dose during childhood
[10, 14].
Outbreak notification
On 9 May 2011, the state public health authority
requested the Robert Koch Institute (RKI) to support
the investigation of an unusually high number of
measles cases in district X, Berlin, Germany. The
district is one of 12 districts in Berlin with about
250000 inhabitants. Fourteen case-patients had been
notified to the district health authority of which
10 were laboratory-confirmed. The first case-patient
had rash onset on 15 April 2011. District X had
0–9 measles cases per year from 2006 to 2010 [7]
and school entry medical examinations of children
aged 5–6 years indicated that the two-dose MCV
(MCV2) coverage in district X was 88·5% in 2010
and 91·1% in 2011.
The district health authority had identified two
clusters of case-patients in area A that could be related
or unrelated. One in the community of area A charac-
terized by apartment blocks and a centrally located
shopping centre and the other associated with a
4-day school trip (26–29 April 2011) taken by 55
students from an anthroposophic school located
within area A.
We aimed to describe the outbreak by time, place
and person, to estimate vaccine effectiveness (VE),
to identify risk groups, to formulate control measures,
and to assess whether all cases were attributable to the
same outbreak.
METHODS
We used structured questionnaires to interview case-
patients in the community by telephone. The data
was used to describe the case-patients by time, place,
vaccination status, demographic and clinical factors.
Additionally, we conducted a retrospective cohort
study to calculate attack rates (ARs) in vaccinated
and unvaccinated school-trip participants and to esti-
mate VE. Differences in medians were tested using
the Mann–Whitney test on a 5% significance level.
The data were analysed using Stata (version 12.0,
StataCorp LP, USA) and Excel 2003 (Microsoft
Corporation, USA).
Case definition
We defined a probable case as a person presenting
with a generalized rash for >3 days with fever and
either cough, a runny nose, red eyes or Koplik’s
spots with symptom onset between 1 April and
31 July 2011 in people living, working or attending
school in district X. We defined a confirmed case
as a probable case with laboratory confirmation
[detection of MV-specific IgM antibodies or MV
genome using polymerase chain reaction (PCR)].
We classified a case-patient as a ‘school-trip case’
if the case-patient had participated in the school trip
occurring on 26–29 April 2011. A case-patient not
participating in the school trip was classified as a
‘community case’.
We defined secondary cases as those occurring in
contacts of a probable or confirmed case-patient for
whom rash onset was 7–21 days after contact with
the primary case.
Case finding
We used routine patient notifications made to the
district health authority by doctors and laboratories.
Using email and regular meetings other district health
authorities in Berlin were asked about measles case-
patients falling under the case definitions.
We searched actively for cases by (a) asking
case-patients if they knew of others with measles,
(b) reviewing data from the National Reference
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Laboratory and (c) sending letters to all local paedia-
tricians, general practitioners, schools and nurseries.
The school doctor identified school-trip cases by call-
ing parents of all school-trip participants and children
who reported ill to the school.
Calculation of VE
The school checked vaccination cards of all students
and collected information on doses received of MCV
and participation in the school trip on an anonymous
form. Using exact Poisson regression, we calculated
incidence rate ratios (IRR) and VE (VE=1– IRR)
with 95% confidence intervals (CI) for one and two
doses of MCV.
Laboratory investigation
The German National Reference Centre Measles,
Mumps, Rubella (NRC) conducted laboratory con-
firmation of suspected cases and MV genotyping.
Private laboratories also performed serological test-
ing. MV-specific IgM and IgG antibodies were deter-
mined in serum samples using commercially avail-
able enzyme-linked immunosorbent assays (ELISA,
EUROIMMUN AG, Germany). MV genome was
detected by reverse transcription (RT)–PCR, as
described previously [15]. RT–PCR was performed
on throat swabs, oral fluid and urine samples collected
within 7 days after onset of exanthema. In addition
to routine sample collection by treating physicians,
members of the outbreak investigation team made
home visits to collect throat swabs and urine samples.
Genotyping of detected MV was performed accord-
ing to WHO recommendations [16] and has been
described in detail previously [17, 18]. The sequence
data obtained, the genotype information, the official
WHOMV sequence name, and relevant epidemiologi-
cal data were submitted to GenBank and the WHO





We identified a total of 73 measles case-patients;
35 probable and 38 confirmed cases. Of these, 39
were community case-patients, 20 were children who
participated in the school trip, and 14 were friends
or family members of the school-trip case-patients
(Fig. 1). Of the 72 case-patients with known gender
41 (57%) were female. Age was reported for 59 case-
patients, 16 (27%) were aged 520 years of age.
Of all case-patients, 11 (15%) were hospitalized. The
outbreak peaked in calendar week 19 (Fig. 1).
Community cases
The number of community case-patients peaked in
calendar weeks 17–19 (Fig. 1). Of the 39 community
case-patients, 26 (67%) were female and 14 (38%)
were aged 520 years (Fig. 2). Twelve of the 14 com-
munity case-patients aged 520 years were female.
Three case-patients were aged <1 year. The overall
median age was 14 years: for male cases it was
12 years (range 0–36), while the median age of female
cases was statistically significantly higher at 17 years
(range 0–44) (P=0·020). Of 16 community case-
patients with available information, 10 (63%) were
hospitalized (three were aged 41 year and seven
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Fig. 1 [colour online]. Measles cases in the outbreak in
district X, Berlin, Germany, 2011, by week of onset of
rash (n=60). Date of rash onset missing for 13 cases.
Measles outbreak in Berlin, Germany, 2011 791
Of 32 community case-patients with known vacci-
nation status 27 (84%) were unvaccinated, five (16%)
had received one dose and none had received
two doses of MCV. Four case-patients had received
vaccination 521 days before disease onset. One case-
patient had received MCV1 as a post-exposure vacci-
nation 4 days after symptom onset of his sibling
and developed measles disease 10 days after the
vaccination. District of residence was known for
36/39 case-patients: 31 (86%) lived in district X and
five (14%) lived in three other districts of Berlin, but
worked or went to school in district X. Number of
days from onset of symptoms to notification at the
local health authorities (n=23) ranged from 3 to 23
days (median 8 days). Number of days from diagnosis
to notification at the local health authority (n=18)
ranged from 0 to 9 days (median 1 day).
School-trip cases
Twenty of 55 school-trip participants developed
measles. The primary case-patient, child A, had
symptom onset (fever, cough and runny nose) on the
third day of the 4-day trip, the first week of the peak
in the number of community cases, which suggests
exposure in the community (Fig. 1). Child A had
rash onset in week 18. All other school-trip case-
patients developed rash 8–13 days after child A’s
rash onset. Case-patients were aged 7–10 years and
eight (42%) of 19 with known gender were female.
No hospitalizations were reported for the school-trip
case-patients. Of the 20 students with probable and
confirmed measles, 18 were unvaccinated and vacci-
nation status was unknown for two. Of the remaining
35 school-trip participants, 26 (74%) had received two
doses of MCV, six (17%) had received one dose, one
(3%) had received no vaccination and two (6%) had
unknown vaccination status (Table 1). After excluding
students with unknown vaccination status, the AR
was 94% (18/19) in unvaccinated students. No cases
occurred in vaccinated students (one or two doses).
Based on the IRR, VE for MCV1 was estimated at
87·6% (95% CI 28·0–100) and VE for MCV2 at
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Fig. 2 [colour online]. Age and sex distribution of community cases in district X measles outbreak, Berlin, Germany, 2011
(n=37).
Table 1. Vaccination status of children participating in the school trip,









effectiveness (%) 95% CI
0 18 1 Ref.
1 0 6 87·6 28·0–100
2 0 26 97·1 83·4–100
Total 18 33
CI, Confidence interval.
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Laboratory results
Of the 73 case-patients, 38 (52%) were laboratory
tested and the result known. All were positive for
acute measles infection. Eight (11%) were laboratory
tested but with unknown result. MV genotyping
was successful for 26 cases: community case-patients
(n=6), school-trip case-patients (n=14) and their
secondary cases (n=6); all had the same variant
of MV genotype D4 (MVs/Berlin.DEU/18.11). In
the 450 nucleotide sequence used for genotyping
this MV variant was identical to MVs previously
detected in France (i.e. MVs/Toulon.FRA/03.11,
MVs/ClermontFerrand.FRA/09.11) and a MV that
was imported to Slovenia from France (MVs/
Ljubljiana.SVN/15.11) [19]. At the time of the out-
break investigation, a MV variant exhibiting sequence
identity to MVs/Berlin.DEU/18.11 was not detected
in any other measles case in Germany.
Control measures
The district health authorities checked the vaccination
cards of families and at schools and nurseries with one
or more children with measles, announced school/
nursery/work exclusions, gave recommendations on
post-exposure vaccinations and sent information letters
to local doctors and schools informing them of the
outbreak and reminding them of their notification
duty and the measles management guidelines. The
local population was informed through a press release.
On 2 May 2011, the Monday following the school
trip, the children attended school except child A,
who on that day had developed a rash (<4 days
after returning from the school trip) (Fig. 3). The diag-
nosis of measles was confirmed and reported to the
school on 5 May. On the same day, the school
informed parents of children who participated in the
trip. All school-trip participants without documented
vaccinations were excluded from school. However,
the children had attended school until 7 days after
the first exposure to measles. The second case
among school-trip participants had symptoms and
rash onset after the implementation of the school
exclusion and no other case occurred in students not
attending the school trip.
Vaccination cards of all students were checked in
order to assess the vaccination coverage and possible
extent of a measles outbreak at the school and to
plan for appropriate control measures in case the
exclusion of school-trip participants had been intro-
duced too late. Of the 381 students, 95 (25%) were
unvaccinated before the outbreak, 95 (25%) had
unknown vaccination status, 65 (17%) had one vacci-
nation, 121 (32%) had two vaccinations, and five (1%)
had a documented history of measles. After being
informed of the outbreak, parents of 34 students
took their child to be vaccinated at a private physician
during May 2011: 24 students received their first dose
and 10 their second dose of MCV.
DISCUSSION
The outbreak investigation showed that district





















Fig. 3 [colour online]. School-trip cases in district X measles outbreak, Berlin, Germany, 2011, by date of rash onset (n=17).
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73 probable and confirmed case-patients between
April and July 2011 caused by MVgenotype D4
(MVs/Berlin.DEU/18.11). Child A was exposed to
measles in the community and introduced it to school-
trip participants from an anthroposophic school.
This was the largest measles outbreak in Berlin since
the introduction of the electronic notification system
in 2001. Of community case-patients, 38% were aged
520 years. Hospitalizations occurred in the very
young and adult case-patients. Of school-trip partici-
pants, none of the vaccinated children developed
measles despite being exposed through shared activi-
ties, e.g. sitting on the same bus for several hours.
This translates into a very high MCV2 VE. Ex-
cept for school-trip participants, no additional cases
of measles were identified at the school despite the
high proportions of unvaccinated students and
students with unknown vaccination status. The exclu-
sion of unvaccinated school-trip participants as late
as 7 days after first exposure was thus an effective con-
trol measure in this setting.
We found a two-dose VE of 97·1% which corre-
sponds with the two-dose VE of 99·4% (95% CI
97–100) reported from a large school outbreak in
Germany in 2006 [20] and a VE found in a review
of field effectiveness of MCVs (two-dose VE 94·1%,
95% CI 88·3–98·3) [21]. The MCV1 VE estimation
was limited by the low number of children with one
vaccination resulting in a wide 95% CI.
The WHO recommends a 95% MCV2 coverage to
eliminate measles from the WHO European region
by 2015 [1, 22] in order to hinder community out-
breaks caused by accumulation of susceptible individ-
uals. Measles vaccination is voluntary in Germany
and differences exist between federal states (lowest
coverage in Southwest Germany), between districts
within federal states and can be particularly low in
specific local settings such as anthroposophic schools.
In district X and overall in Berlin, MCV2 coverage
has not reached the target of 95%. The below target
coverage and the results of our study highlight the
fact that vaccination coverage in local settings (e.g.
schools) can be far below the state level, which can
be a source or multiplier for localized outbreaks.
The outbreak described here was not the first out-
break in Berlin in recent years. Berlin experienced
an outbreak in a population with critical attitudes
towards vaccination in 2010 with at least 62 cases
with a mean age of 10·5 years [11]. A measles sero-
prevalence study of children and adolescents aged
0–17 years in Germany enrolled between May 2003
and May 2006, found that 7·7% of 10- to 17-year-olds
were seronegative for measles [23]. The low vacci-
nation coverage for MCV2, the estimated high pro-
portion of seronegatives among adolescents, as well
as the recent outbreaks are signs of pockets of suscep-
tible individuals in the adult and anthroposophic
population of district X and Berlin. This outbreak
thus showed that pockets of susceptible people con-
tinue to be present in Germany, as also seen in pre-
vious outbreaks [24–26]. Additionally, adult women
seem to be at higher risk of measles infection, which
may be due to either more exposure through contact
with children or less catch-up possibilities than men,
who are more likely to be vaccinated through military
service.
This outbreak investigation confirmed that two
doses of MCV are highly effective in preventing
measles disease. Therefore the outbreak was not due
to vaccination failure, but due to low vaccination
coverage, which also applied to affected adults.
The introduction of a two-dose schedule in 1991
and increasing vaccination coverage of later birth
cohorts diminished the circulation of MV, thus reduc-
ing chances of exposure to the virus for later gener-
ations. However, a considerable proportion of adults
aged 20–40 years, i.e. birth cohorts from around
1970–1990 are still susceptible, which can be explained
by low vaccination coverage in the first two decades
of infant measles immunization. This supports the
recommendation of administering a catch-up MCV1
or MCV2 to everyone born after 1970 with incomplete
or unknown vaccination status.
Genotyping and further genetic subtyping con-
firmed that all case-patients living in district X
and case-patients working or attending school in dis-
trict X were indeed part of the outbreak. MV variants
of genotype D4 have caused outbreaks in Europe
since 2007 and D4 became the predominant genotype
in Europe in 2011 [4, 27]. The MV variant responsible
for the outbreak in district X circulated in France
during the first and second quarters of 2011 [19].
No other case of this MV variant was identified in
Germany prior to the outbreak investigation. This
indicates that the outbreak was probably initiated
by introduction of the MV from another country.
The source of MV importation is unknown since the
index case could not be identified.
Laboratory testing of suspected measles case-
patients is not mandatory in Germany. The costs
are, however, covered by the NRC. In the past,
it was documented that underreporting as well as
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delayed diagnosis and reporting of measles is not
uncommon in Germany [28]. We identified case-
patients using notification data and active case
finding and identified five community case-patients
living in other districts in Berlin. However, after
closure of the outbreak investigation 11 additional
case-patients with detection of the sequence MVs/
Berlin.DEU/18.11 and disease onset before 31 July
2011 were identified at the NRC. Eight were living
in Berlin. Three were living in another federal state
and were probably infected by a relative living in
Berlin. We were, however, unable to establish district
X as the place of infection. The temporal distribution
suggests that these 11 cases belong to the transmission
chain initiated by the MV spread in district X.
The presence of obviously existing unrecognized epi-
demiological links between cases in Berlin high-
lights the importance of laboratory investigations
and communication between different district health
authorities and the laboratory as well as active case
finding when investigating a community outbreak.
In this outbreak, 27% of all case-patients and 38%
of community case-patients were aged 520 years.
The general shift towards older age groups reported
in outbreaks in Germany since 2001 [10] is thus seen
for the community where it was similar to the 35·2%
reported for Europe in 2011 [4]. The overall pro-
portion of 15% hospitalized cases in this outbreak
was lower than in Europe in 2011, where the pro-
portion was 28% [4]; however, in community cases
63% were hospitalized.
The delayed case notification made it difficult to
implement control measures. For community case-
patients risk of transmission was also seen as some
cases were sent home with an initial diagnosis of an
allergic reaction or were hospitalized for several days
without a measles diagnosis.
Exclusion from school of unvaccinated school-trip
participants was delayed by late reporting of
the measles diagnosis of child A until day 8 after
exposure. Thanks to the swift reaction of the
school doctor and school directorate, exclusion was
implemented in time to avoid secondary cases in
students not participating in the trip. Given the low
vaccination coverage of the pupils at the school and
the reproduction rate of measles, this exclusion may
have prevented up to 190 additional cases in students
with unknown vaccination status or known to be
unvaccinated. Additionally, the information on the
outbreak increased the number of students who
received one or two doses of MCV.
RECOMMENDATIONS
In order to achieve measles elimination in Germany
by 2015, vaccination coverage in children, ado-
lescents, and young adults needs to be improved.
This requires information and promotion campaigns
targeted both at the public and at primary-care
physicians including occupational health doctors and
gynaecologists who see adolescent and adult patients.
Physicians need to be reminded of the importance of
rapid laboratory diagnosis and notification of sus-
pected measles case-patients in order to allow timely
implementation of control measures. School exclusion
of exposed unvaccinated individuals is an important
intervention even after occurrence of a single case in
order to interrupt transmission of measles, especially
in communities with low vaccination coverage or
reluctance to implement immediate mass vaccination
in response to the outbreak. Surveillance including
MV genotyping should be continued during outbreaks
to assess the circulation period of an imported MV.
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